ProQR Therapeutics Says Ophthalmology Drug Gets Fast Track Designation

ProQR Therapeutics said Wednesday its QR-110 for the treatment of Leber’s congenital amaurosis type 10 has received fast track designation from the U.S. Food and Drug Administration.

The rare genetic disease causes individuals to lose sight, often in the first years of life. QR-110 is an RNA oligonucleotide targeting LCA 10 due to the p.Cys998X mutation, the company said. The company said it will launch its first trial for QR-110 as a multidose study and for that it will benefit from the fast track designation.

Leave a Comment